Spots Global Cancer Trial Database for tykerb
Every month we try and update this database with for tykerb cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Pazopanib, Lapatinib or Trastuzumab in Subjects With Solid Tumors | NCT01454804 | Advanced Cancer... | Pazopanib Lapatinib Trastuzumab (He... Pazopanib | - | M.D. Anderson Cancer Center | |
| Bevacizumab in Multiple Phase I Combinations | NCT00543504 | Advanced Cancer | Bevacizumab Sorafenib Erlotinib Trastuzumab Lapatinib Sunitinib Cetuximab | - | M.D. Anderson Cancer Center | |
| Bevacizumab in Multiple Phase I Combinations | NCT00543504 | Advanced Cancer | Bevacizumab Sorafenib Erlotinib Trastuzumab Lapatinib Sunitinib Cetuximab | - | M.D. Anderson Cancer Center | |
| Bevacizumab and Lapatinib in Children With Recurrent or Refractory Ependymoma | NCT00883688 | Brain Cancer Pediatric Cance... | Bevacizumab Lapatinib | - 21 Years | M.D. Anderson Cancer Center | |
| Pazopanib, Lapatinib or Trastuzumab in Subjects With Solid Tumors | NCT01454804 | Advanced Cancer... | Pazopanib Lapatinib Trastuzumab (He... Pazopanib | - | M.D. Anderson Cancer Center | |
| Lapatinib With Sirolimus or Metformin | NCT01087983 | Advanced Cancer... | Lapatinib Sirolimus Metformin | - | M.D. Anderson Cancer Center | |
| Pazopanib Plus Lapatinib Compared To Lapatinib Alone In Subjects With Inflammatory Breast Cancer | NCT00558103 | Neoplasms, Brea... | lapatinib Pazopanib | 18 Years - | GlaxoSmithKline | |
| Pazopanib (VOTRIENT) Plus Paclitaxel (TAXOL), Pazopanib Plus Paclitaxel (TAXOL) Plus Carboplatin (PARAPLATIN), and Pazopanib Plus Paclitaxel (TAXOL) Plus Lapatinib (TYKERB) | NCT00388076 | Neoplasms, Brea... | Pazopanib Lapatinib paclitaxel carboplatin | 18 Years - | GlaxoSmithKline | |
| Pazopanib, Lapatinib or Trastuzumab in Subjects With Solid Tumors | NCT01454804 | Advanced Cancer... | Pazopanib Lapatinib Trastuzumab (He... Pazopanib | - | M.D. Anderson Cancer Center | |
| GW572016 In Patients With Advanced Or Metastatic Breast Cancer | NCT00462956 | Neoplasms, Brea... | Tykerb | 20 Years - 40 Years | GlaxoSmithKline | |
| EAP (Expanded Access Protocol) Of Lapatinib Combined With Capecitabine In Metastatic Breast Cancer | NCT00338247 | Neoplasms, Brea... | lapatinib + cap... | 18 Years - | Novartis | |
| Bevacizumab in Multiple Phase I Combinations | NCT00543504 | Advanced Cancer | Bevacizumab Sorafenib Erlotinib Trastuzumab Lapatinib Sunitinib Cetuximab | - | M.D. Anderson Cancer Center | |
| Concentration and Activity of Lapatinib in Vestibular Schwannomas | NCT00863122 | Vestibular Schw... NF2 Neurofibromatos... Acoustic Neurom... Auditory Tumor | lapatinib | 18 Years - | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in ErbB2 (HER2) Positive Metastatic Breast Cancer | NCT00820222 | Metastases, Bra... | capecitabine lapatinib trastuzumab | 18 Years - | Novartis | |
| Concentration and Activity of Lapatinib in Vestibular Schwannomas | NCT00863122 | Vestibular Schw... NF2 Neurofibromatos... Acoustic Neurom... Auditory Tumor | lapatinib | 18 Years - | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| Lapatinib + Vinorelbine in ErbB2 Overexpressing, First or Second Line Metastatic Breast Cancer Subjects | NCT00709618 | Neoplasms, Brea... | Lapatinib, Vino... | 18 Years - | GlaxoSmithKline | |
| Concentration and Activity of Lapatinib in Vestibular Schwannomas | NCT00863122 | Vestibular Schw... NF2 Neurofibromatos... Acoustic Neurom... Auditory Tumor | lapatinib | 18 Years - | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| Pazopanib Plus Lapatinib Compared To Lapatinib Alone In Subjects With Inflammatory Breast Cancer | NCT00558103 | Neoplasms, Brea... | lapatinib Pazopanib | 18 Years - | GlaxoSmithKline | |
| Brain Metastases In ErbB2-Positive Breast Cancer | NCT00437073 | Neoplasms, Brea... | capecitabine topotecan lapatinib | 18 Years - | GlaxoSmithKline | |
| Pazopanib, Lapatinib or Trastuzumab in Subjects With Solid Tumors | NCT01454804 | Advanced Cancer... | Pazopanib Lapatinib Trastuzumab (He... Pazopanib | - | M.D. Anderson Cancer Center | |
| Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in ErbB2 (HER2) Positive Metastatic Breast Cancer | NCT00820222 | Metastases, Bra... | capecitabine lapatinib trastuzumab | 18 Years - | Novartis |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
